BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30712867)

  • 1. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
    Yin C; Zhu B; Zhang T; Liu T; Chen S; Liu Y; Li X; Miao X; Li S; Mi X; Zhang J; Li L; Wei G; Xu ZX; Gao X; Huang C; Wei Z; Goding CR; Wang P; Deng X; Cui R
    Cell; 2019 Feb; 176(5):1113-1127.e16. PubMed ID: 30712867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence That STK19 Is Not an NRAS-dependent Melanoma Driver.
    Rodríguez-Martínez M; Boissiére T; Noe Gonzalez M; Litchfield K; Mitter R; Walker J; Kjœr S; Ismail M; Downward J; Swanton C; Svejstrup JQ
    Cell; 2020 Jun; 181(6):1395-1405.e11. PubMed ID: 32531245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.
    Qian L; Chen K; Wang C; Chen Z; Meng Z; Wang P
    Clin Cancer Res; 2020 Jul; 26(13):3408-3419. PubMed ID: 32156748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STK19: a new target for NRAS-driven cancer.
    Asquith CRM; Temme L
    Nat Rev Drug Discov; 2020 Sep; 19(9):579. PubMed ID: 32587355
    [No Abstract]   [Full Text] [Related]  

  • 5. Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion.
    McConnell AM; Mito JK; Ablain J; Dang M; Formichella L; Fisher DE; Zon LI
    Dev Biol; 2019 May; 449(2):107-114. PubMed ID: 29883661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
    Forloni M; Dogra SK; Dong Y; Conte D; Ou J; Zhu LJ; Deng A; Mahalingam M; Green MR; Wajapeyee N
    Elife; 2014 Feb; 3():e01460. PubMed ID: 24550252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.
    Puig-Butillé JA; Badenas C; Ogbah Z; Carrera C; Aguilera P; Malvehy J; Puig S
    Exp Dermatol; 2013 Feb; 22(2):148-50. PubMed ID: 23362874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
    Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
    J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
    Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
    Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.
    Zingg D; Debbache J; Peña-Hernández R; Antunes AT; Schaefer SM; Cheng PF; Zimmerli D; Haeusel J; Calçada RR; Tuncer E; Zhang Y; Bossart R; Wong KK; Basler K; Dummer R; Santoro R; Levesque MP; Sommer L
    Cancer Cell; 2018 Jul; 34(1):69-84.e14. PubMed ID: 30008323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational status of naevus-associated melanomas.
    Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
    Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.
    Fedorenko IV; Gibney GT; Smalley KS
    Oncogene; 2013 Jun; 32(25):3009-18. PubMed ID: 23069660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablation of epidermal RXRα in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas.
    Chagani S; Wang R; Carpenter EL; Löhr CV; Ganguli-Indra G; Indra AK
    BMC Cancer; 2017 Nov; 17(1):736. PubMed ID: 29121869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
    Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R
    Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GAB2 induces tumor angiogenesis in NRAS-driven melanoma.
    Yang Y; Wu J; Demir A; Castillo-Martin M; Melamed RD; Zhang G; Fukunaga-Kanabis M; Perez-Lorenzo R; Zheng B; Silvers DN; Brunner G; Wang S; Rabadan R; Cordon-Cardo C; Celebi JT
    Oncogene; 2013 Aug; 32(31):3627-37. PubMed ID: 22926523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
    Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang HB; Pan Y; Liu S; Chung YR; Abdel-Wahab O; Merghoub T; Rossi M; Kudchadkar RR; Lawson DH; Khuri FR; Lonial S; Chen J
    Mol Cell; 2018 Mar; 69(6):923-937.e8. PubMed ID: 29547721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.